Answers are grounded in this paper and cite their sources.
Aim: This meta-analysis compared incidence of grade 3–4 neutropenia with ALK inhibitors versus chemotherapy in patients with non-small-cell lung cancer. Materials & methods: PubMed/MEDLINE was searched to identify Phase II and III randomized clinical trials published up to 25 October 2018. Summary incidence, relative risk and corresponding 95% CIs were calculated for grade 3–4 neutropenia. Results: Five randomized clinical trials were included. Relative risk (95% CI) of developing grade 3–4 neutropenia with ALK inhibitor versus chemotherapy was 0.27 (0.07–1.06). Probabilities of developing grade 3–4 neutropenia were 6.56 and 14.19%, respectively; no significant difference was found. Conclusion: In patients with non-small-cell lung cancer, incidence of grade 3–4 neutropenia with ALK-targeted therapy is not significantly different compared with chemotherapy.
No takes yet. Share an insight, caveat, or question.
Rapoport et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: